Yuze Hua

1.0k total citations · 1 hit paper
14 papers, 670 citations indexed

About

Yuze Hua is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Yuze Hua has authored 14 papers receiving a total of 670 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Yuze Hua's work include Pancreatic and Hepatic Oncology Research (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Immunotherapy and Immune Responses (3 papers). Yuze Hua is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Neuroendocrine Tumor Research Advances (3 papers) and Immunotherapy and Immune Responses (3 papers). Yuze Hua collaborates with scholars based in China, Germany and Saudi Arabia. Yuze Hua's co-authors include Yong Li, Wei Xiong, Boyao Yu, Yongzhen Mo, Qianjin Liao, Bo Xiang, Daixi Ren, Zhaoyang Zeng, Guiyuan Li and Yujuan Zhou and has published in prestigious journals such as SHILAP Revista de lepidopterología, Molecular Cancer and Cancer Letters.

In The Last Decade

Yuze Hua

11 papers receiving 670 citations

Hit Papers

Mechanisms of vasculogenic mimicry in hypoxic tumor micro... 2021 2026 2022 2024 2021 100 200 300

Peers

Yuze Hua
Boyao Yu China
Kristina Stumpf United States
Martin Nurmik Luxembourg
He Dou China
Emily N. Arner United States
Boyao Yu China
Yuze Hua
Citations per year, relative to Yuze Hua Yuze Hua (= 1×) peers Boyao Yu

Countries citing papers authored by Yuze Hua

Since Specialization
Citations

This map shows the geographic impact of Yuze Hua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuze Hua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuze Hua more than expected).

Fields of papers citing papers by Yuze Hua

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuze Hua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuze Hua. The network helps show where Yuze Hua may publish in the future.

Co-authorship network of co-authors of Yuze Hua

This figure shows the co-authorship network connecting the top 25 collaborators of Yuze Hua. A scholar is included among the top collaborators of Yuze Hua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuze Hua. Yuze Hua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
Hua, Yuze, Sen Yang, Vincent Liu, et al.. (2025). Epigenetic modification and tumor immunity: Unraveling the interplay with the tumor microenvironment and its therapeutic vulnerability and implications. Cancer Letters. 616. 217587–217587. 2 indexed citations
2.
Lu, Junliang, Liangrui Zhou, Taiping Zhang, et al.. (2025). Molecular profiling reveals the malignant potential in solid pseudopapillary neoplasms of the pancreas. Cancer Letters. 625. 217788–217788. 1 indexed citations
3.
Yuan, Shangqin, Yuze Hua, Sen Yang, et al.. (2025). Neoantigens in the application of adoptive cell therapy for solid tumors. SHILAP Revista de lepidopterología. 8(3). 155–168.
4.
Zhang, Yalu, Ronghua Zhang, Jiayi Li, et al.. (2025). Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58. Journal for ImmunoTherapy of Cancer. 13(9). e012163–e012163.
5.
Hua, Yuze, Sen Yang, Yalu Zhang, et al.. (2024). Modulating ferroptosis sensitivity: environmental and cellular targets within the tumor microenvironment. Journal of Experimental & Clinical Cancer Research. 43(1). 19–19. 27 indexed citations
6.
8.
Yang, Sen, Yuze Hua, Qiaofei Liu, & Quan Liao. (2024). Long-term sustained clinical remission of peritoneal metastatic pancreatic ductal adenocarcinoma after sequential chemoradiation therapy: a case report. SHILAP Revista de lepidopterología. 7(3). 233–236.
9.
Liu, Qiaofei, Jiayi Li, Sen Yang, et al.. (2023). Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Molecular Cancer. 22(1). 28–28. 89 indexed citations
10.
Yang, Sen, Yalu Zhang, Yuze Hua, et al.. (2023). Comprehensive analysis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs): A SEER database analysis of 767 cases. Frontiers in Oncology. 12. 1007317–1007317. 3 indexed citations
11.
12.
Yang, Sen, Yalu Zhang, Yuze Hua, et al.. (2022). GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Frontiers in Oncology. 12. 968610–968610. 9 indexed citations
13.
Chen, Yunhua, Xianjie Jiang, Peng Miao, et al.. (2021). Mechanisms of vasculogenic mimicry in hypoxic tumor microenvironments. Molecular Cancer. 20(1). 7–7. 304 indexed citations breakdown →
14.
Ren, Daixi, Yuze Hua, Boyao Yu, et al.. (2020). Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy. Molecular Cancer. 19(1). 19–19. 218 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026